Dr. Hill and Dr. Sauter Discuss the Future of CAR T-Cell Products Agents in Lymphoma

Craig Sauter, MD, is director of the Blood and Marrow Transplant Program at Cleveland Clinic. Brian T. Hill, MD, PhD, is director of the Lymphoid Malignancies Program and a staff physician at the Cleveland Clinic Taussig Cancer Institute. In this interview, they look at research that could affect the future of CAR T-cell therapy.

Hill noted that half of patients have a complete, durable remission with CAR T-cell therapy and, of those, approximately one-third of patients experience recurrence.

Dr Sauter said the development of allogeneic products would be a "win" for patients, but it is important to demonstrate that these agents can induce durable remission. Investigators have to go beyond just improving CAR T-cell products, but also must study all the environmental factors that can affect efficacy.